Abstract
Therapeutic benefits of alpha1-adrenergic antagonists (A1As), namely, prazosin, terazosin and doxazosin, have begun to emerge in a broad range of psychiatric disorders in clinical trials. A1As have shown promise in the treatment of several psychiatric disorders such as posttraumatic stress disorder (PTSD), alcohol dependence, cocaine dependence, nicotine cessation and dementia-related agitation in both animal and human studies. These, and other chronic psychiatric conditions, may be mediated or precipitated by stressful conditions. A1As beneficial effects in these psychiatric disorders are hypothesized via their unique effects on regulating norepinephrine (NE) and corticotrophin releasing factor (CRF), which are two key mediators of stress in the central nervous system (CNS). Despite increasing use of A1As in psychiatric disorders, there is a lack of comprehensive review. Animal studies have suggested that by regulating NE in stressful conditions, A1As can increase the pre-frontal cortical functioning and decrease amygdalar activity. Similarly, rat studies have shown a direct decrease in cerebrospinal fluid (CSF) expression of CRF in rats treated with prazosin in stressful conditions. Thus, A1As may have potential benefit in the treatment and secondary prevention of stress-mediated or precipitated psychiatric disorders. In addition, another beneficial effect of A1As is known to be on improvement of metabolic parameters such as lipid profile and insulin sensitivity.
Keywords: Alpha1-adrenergic receptor antagonists, doxazosin, prazosin terazosin, PTSD, secondary prevention in psychiatric disorders, stress, substance use disorders.
Current Psychopharmacology
Title:Alpha1-Adrenergic Receptor Antagonists Use in Treatment and Prevention of Psychiatric Disorders: A Review
Volume: 3
Author(s): Abhishek Wadhawan, Alok Banga, Yinghui Duan, Michel Mennesson and Zhao Helen Wu
Affiliation:
Keywords: Alpha1-adrenergic receptor antagonists, doxazosin, prazosin terazosin, PTSD, secondary prevention in psychiatric disorders, stress, substance use disorders.
Abstract: Therapeutic benefits of alpha1-adrenergic antagonists (A1As), namely, prazosin, terazosin and doxazosin, have begun to emerge in a broad range of psychiatric disorders in clinical trials. A1As have shown promise in the treatment of several psychiatric disorders such as posttraumatic stress disorder (PTSD), alcohol dependence, cocaine dependence, nicotine cessation and dementia-related agitation in both animal and human studies. These, and other chronic psychiatric conditions, may be mediated or precipitated by stressful conditions. A1As beneficial effects in these psychiatric disorders are hypothesized via their unique effects on regulating norepinephrine (NE) and corticotrophin releasing factor (CRF), which are two key mediators of stress in the central nervous system (CNS). Despite increasing use of A1As in psychiatric disorders, there is a lack of comprehensive review. Animal studies have suggested that by regulating NE in stressful conditions, A1As can increase the pre-frontal cortical functioning and decrease amygdalar activity. Similarly, rat studies have shown a direct decrease in cerebrospinal fluid (CSF) expression of CRF in rats treated with prazosin in stressful conditions. Thus, A1As may have potential benefit in the treatment and secondary prevention of stress-mediated or precipitated psychiatric disorders. In addition, another beneficial effect of A1As is known to be on improvement of metabolic parameters such as lipid profile and insulin sensitivity.
Export Options
About this article
Cite this article as:
Wadhawan Abhishek, Banga Alok, Duan Yinghui, Mennesson Michel and Helen Wu Zhao, Alpha1-Adrenergic Receptor Antagonists Use in Treatment and Prevention of Psychiatric Disorders: A Review, Current Psychopharmacology 2014; 3 (3) . https://dx.doi.org/10.2174/2211556004666150507220211
DOI https://dx.doi.org/10.2174/2211556004666150507220211 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Abnormalities of Peptide Metabolism in Alzheimer Disease
Current Neurovascular Research The Development of Topically Acting Carbonic Anhydrase Inhibitors as Antiglaucoma Agents
Current Pharmaceutical Design Practical Recommendations for Familial Combined Hyperlipidemia Diagnosis and Management: An Update
Vascular Disease Prevention (Discontinued) Cognitive Decline as a Consequence of Essential Hypertension
Current Pharmaceutical Design Depression and Anxiety Levels Increase Chronic Musculoskeletal Pain in Patients with Alzheimer's Disease
Current Alzheimer Research Enhancing Central Nervous System Endogenous GLP-1 Receptor Pathways for Intervention in Alzheimers Disease
Current Alzheimer Research Assembly, Maturation, and Trafficking of the γ-Secretase Complex in Alzheimers Disease
Current Alzheimer Research Smart Community Care System: Ambient Intelligence Using Radio Frequency Identification (RFID) and Mobile Agent
Recent Patents on Computer Science The Role of Immune and Inflammatory Mechanisms in ALS
Current Molecular Medicine Editorial: Circadian Rhythms are Everywhere: Except in Neurodegenerative Disorders
Current Alzheimer Research Coenzyme Q10 Reduction with Statins: Another Pleiotropic Effect
Current Drug Therapy Quality Control Optimization Solutions for Determination of Rutin in Supplements Containing Ginkgo Biloba Extract
Current Pharmaceutical Analysis Role of Nitric Oxide in Motor Control: Implications for Parkinsons Disease Pathophysiology and Treatment
Current Pharmaceutical Design A Synthesis of Functional Neuroimaging in the Frontal Variant of Frontotemporal Dementia
Current Medical Imaging Treating High Density Lipoprotein Cholesterol (HDL-C): Quantity Versus Quality
Current Pharmaceutical Design Histone Deacetylase (HDAC) Inhibitors as Potential Drugs to Target Memory and Adult Hippocampal Neurogenesis
Current Psychopharmacology Therapeutic Approaches to Modulating Glutathione Levels as a Pharmacological Strategy in Alzheimer`s Disease
Current Alzheimer Research 24-Hour Blood Pressure Control – A Predictor for Clinical Outcomes
Current Hypertension Reviews Occupational Complexity and Leisure Activities in Cognitive Aging
Current Psychopharmacology Statin Treatment and the Natural History of Atherosclerotic-Related Diseases: Pathogenic Mechanisms and the Risk-Benefit Profile
Current Pharmaceutical Design